Researchers published a cross‑disciplinary analysis examining how targeted protein degraders (TPDs) could affect human health and nonhuman species. The paper surveys mechanisms, off‑target degradation risks, and potential ecological impacts as TPDs move beyond lab models into broader use. The authors highlight knowledge gaps in long‑term safety, degradation product biology and interspecies susceptibility—areas that require toxicology, environmental surveillance and regulatory frameworks. They call for standardized assays to detect unintended proteome perturbations. Drug developers and regulators will need to integrate these findings into preclinical safety testing and environmental risk assessments as the modality scales across therapeutic areas.